Literature DB >> 9303376

Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.

K M Wasan1, M Ramaswamy, S M Cassidy, M Kazemi, F W Strobel, R L Thies.   

Abstract

The physical characteristics and lipoprotein distribution of free nystatin (NYS) and liposomal NYS (L-NYS) in human plasma were investigated. To determine the percentage of NYS that was lipid associated following incubation in human plasma, C18 reverse-phase extraction columns were used. To assess plasma drug distribution, NYS and L-NYS (20 microg/ml) were incubated in human plasma for 5, 60, and 120 min at 37 degrees C. After each interval, plasma was removed and separated into its lipoprotein and lipoprotein-deficient plasma (LPDP) fractions by ultracentrifugation and assayed for NYS by high-pressure liquid chromatography. Further studies evaluated the liposome structure of L-NYS by filtering through a 0.14-microm-pore-size microfilter before and after the addition of human plasma. When reconstituted L-NYS (mean particle diameter +/- standard deviation, 321 +/- 192 nm) was applied to a C18 column, 67% +/- 4% of the initial NYS concentration was associated with the lipid. When plasma samples containing L-NYS that had been incubated for 5 to 120 min at 37 degrees C were applied to C18 columns, 66 to 76% of the NYS was lipid associated. Incubation of NYS in human plasma for 5 min at 37 degrees C resulted in 3% +/- 1% of the initial NYS concentration incubated in the low-density lipoprotein (LDL) fraction, 23% +/- 4% of that in the high-density lipoprotein (HDL) fraction, and 66% +/- 10% of that in the LPDP fraction. In contrast, the distribution of NYS following incubation of L-NYS in human plasma for 5 min was 13% +/- 2% in the LDL fraction, 44% +/- 5% in the HDL fraction, and 42% +/- 5% in the LPDP fraction. Similar results were observed following 60 and 120 min of incubation. In addition, the liposome structure of L-NYS was quickly lost when mixed with plasma. These findings suggest that rapid disruption of the L-NYS structure upon incubation in human plasma is consistent with its rapid distribution in plasma. The preferential distribution of NYS into the HDL fraction upon incubation of L-NYS may be a function of its phospholipid composition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303376      PMCID: PMC164027          DOI: 10.1128/AAC.41.9.1871

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.

Authors:  K M Wasan; R E Morton
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

2.  Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats.

Authors:  K M Wasan; K Vadiei; G Lopez-Berestein; D R Luke
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

Review 3.  The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.

Authors:  K M Wasan; G Lopez-Berestein
Journal:  Arch Med Res       Date:  1993       Impact factor: 2.235

4.  Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.

Authors:  K M Wasan; R E Morton; M G Rosenblum; G Lopez-Berestein
Journal:  J Pharm Sci       Date:  1994-07       Impact factor: 3.534

5.  Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.

Authors:  M P Selvam; R A Blay; S Geyer; S M Buck; L Pollock; R E Mayner; J S Epstein
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

6.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

Authors:  K M Wasan; M G Rosenblum; L Cheung; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 7.  Oral candidosis: treatment with absorbable and non-absorbable antifungal agents in children.

Authors:  F Dhondt; J Ninane; K De Beule; A Dhondt; G Cauwenbergh
Journal:  Mycoses       Date:  1992 Jan-Feb       Impact factor: 4.377

8.  Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins.

Authors:  K M Wasan; G A Brazeau; A Keyhani; A C Hayman; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.

Authors:  R T Mehta; R L Hopfer; L A Gunner; R L Juliano; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

10.  Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein.

Authors:  K M Wasan; R Perez-Soler
Journal:  J Pharm Sci       Date:  1995-09       Impact factor: 3.534

View more
  9 in total

1.  New nystatin polymeric complexes and their in vitro antifungal evaluation in a model study with Fusarium oxysporum.

Authors:  Ekatherina Charvalos; Aristeidis Tsatsakis; Manolis Tzatzarakis; George Dolapsakis; John Stiakakis
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

2.  Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.

Authors:  Andreas H Groll; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Raul M Alfaro; Christine King; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 3.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.

Authors:  A H Groll; V Petraitis; R Petraitiene; A Field-Ridley; M Calendario; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma.

Authors:  M Ramaswamy; T L Wallace; P A Cossum; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits.

Authors:  A H Groll; D Mickiene; K Werner; R Petraitiene; V Petraitis; M Calendario; A Field-Ridley; J Crisp; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Differences in the lipoprotein distribution of free and liposome-associated all-trans-retinoic acid in human, dog, and rat plasma are due to variations in lipoprotein lipid and protein content.

Authors:  K M Wasan; M Ramaswamy; S P Ng; W Wong; S C Parrott; J O Ojwang; T Wallace; P A Cossum
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

8.  Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.

Authors:  S K Koller-Lucae; H Schott; R A Schwendener
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

9.  Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins.

Authors:  S M Cassidy; F W Strobel; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.